Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq:...
Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALEM, Sept. 8, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq:...
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, August 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (Nasdaq:...
JERUSALEM, Aug. 10, 2026 /PRNewswire/ Scinai Immunotherapeutics Ltd. (NASDAQ: SC NI ) ("Scinai" or t he "Company" ), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd ....